General practitioner‑offered low‑dose CT screening for lung cancer
Official title: Involvement of General Practitioners in Lung Cancer Screening
Run by Assistance Publique - Hôpitaux de Paris · NCT06956040 · Data updated 2026-11-12
This trial tests whether offering yearly low‑dose CT screening through your general practitioner will increase screening participation among high‑risk smokers aged 50–74.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 74 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | June 2, 2025 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | November 20, 2025 |
| Trial ID | NCT06956040 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 50–74 who are current smokers or quit within the last 15 years with ≥20 pack‑years, covered by French social security, able to travel independently to the participating Paris hospitals, and without recent thoracic CT or active severe comorbidity.
✕Probably not a fit
People with prior lung cancer, recent thoracic CT, severe comorbidities or poor functional status, symptomatic or obviously progressive disease, or inability to travel to the study sites are unlikely to benefit from this screening pathway.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study asks GPs to propose low‑dose chest CT screening to patients at high risk for lung cancer and then measures whether those patients complete the initial scan and a repeat scan one year later. Eligible participants are 50–74 years old, current smokers or those who quit within 15 years with at least a 20 pack‑year history, able to attend scans at participating Paris hospitals, and without recent CT or active serious comorbidity. The primary outcome is adherence to the screening pathway defined by initial and one‑year follow‑up scans; secondary data include reasons for nonparticipation and safety signals. The trial is conducted under the Assistance Publique–Hôpitaux de Paris network at Hôpital Cochin and Hôpital Bichat.
Why it matters
Potential benefit: If successful, more high‑risk individuals could complete regular low‑dose CT screening, leading to more cancers being found at an earlier, potentially curable stage.
How similar studies have gone: Large randomized trials like NLST and MILD have shown that low‑dose CT screening reduces lung cancer mortality, but using general practitioners to propose and deliver screening is a more recent implementation approach that has been less extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria : * Adults aged 50-74 * Active smoker or weaned smoker for less than 15 years, of at least 20 pack-years * Affiliation with a social security scheme or CMU (beneficiary or beneficiary entitled) * Written informed consent prior to study participation Exclusion Criteria : * History of lung cancer * Thoracic CT scan performed within the previous year * 1-year follow-up not possible * Inability to travel independently to Hôpital Cochin or Hôpital Bichat for scans * People with severe co-morbidities contraindicating exploration and/or management of lung cancers * People in poor general health (=PS2 and above) * People with a history of cancer under active surveillance by thoracic computed tomography (CT and PET scans) * People with rest dyspnea (=mMRC4) * Recent weight loss, altered general condition or hemoptysis, raising suspicion of progressive lung cancer * Signs of respiratory infection (fever, productive cough) * Patients under guardianship, curatorship or protected adults * Inability to give free written informed consent prior to study participation
Where it's running
-
Hôpital Cochin
Paris, France Recruiting
Study contacts
- Principal investigator: Céline BUFFEL du VAURE, PhD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Céline BUFFEL du VAURE, PhD
- Email: celine.buffel-du-vaure@u-paris.fr
- Phone: 06 61 90 03 71
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.